Gastrointestinal adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the EudraVigilance and VigiAccess databases

被引:0
作者
Rabbani, Syed Arman [1 ]
Khurana, Atul [2 ]
El-Tanani, Mohamed [1 ]
Arora, Mandeep Kumar [2 ]
Sharma, Shrestha [3 ]
Sridhar, Sathvik B. [1 ]
Dubey, Harikesh [4 ]
机构
[1] RAK Med & Hlth Sci Univ, RAK Coll Pharm, Ras Al Khaymah, U Arab Emirates
[2] DIT Univ, Sch Pharmaceut & Populat Hlth Informat, Dehra Dun, India
[3] Amity Univ, Amity Inst Pharm AIP, Gurgaon, India
[4] Michigan State Univ, Inst Quantitat Hlth Sci & Engn, E Lansing, MI USA
关键词
Gastrointestinal adverse events; immune checkpoint inhibitors; pharmacovigilance; EudraVigilance; VigiAccess; oncology;
D O I
10.1080/14740338.2024.2416539
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BackgroundThis study aimed to provide an overview of gastrointestinal (GI) adverse events associated with immune checkpoint inhibitors (ICIs) using two pharmacovigilance databases, EudraVigilance and VigiAccess.Research design and methodsData was collected from the date of ICI's marketing authorization until 30 November 2023. Reporting odds ratio (ROR) was used as a measure of ADR reporting disproportionality for signal detection.ResultsOverall, across both databases, EudraVigilance and VigiAccess, a total of 76,606 ADR reports were analyzed. In EudraVigilance, colitis (12,581) and diarrhea (12,108) were the most reported GI adverse events, with similar findings in VigiAccess. Furthermore, in both databases, the most ADR reports were associated with nivolumab and pembrolizumab. Durvalumab (ROR: 3.96, 95%CI :3.65-4.28), ipilimumab (ROR: 1.95, 95%CI: 1.89-2.01), nivolumab (ROR: 1.05, 95%CI: 1.02-1.07), and atezolizumab (ROR: 1.04, 95%CI: 1.01-1.07) demonstrated higher risks of GI events compared to other ICIs. EudraVigilance analysis identified dysphagia, ascites, hematochezia, and gastroesophageal reflux disease as potential signals associated with ICI therapy. Majority of ADR reports (87.2%) comprised serious GI adverse events, a portion of which was associated with fatal outcomes (14.5%). Atezolizumab (14.9%) and pembrolizumab (11.9%) were linked to a higher incidence of fatal outcomes compared to other ICIs.ConclusionThe differential risk profiles of ICIs-associated-GI adverse events underscore the importance of personalized therapy in oncology.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Adverse events associated with immune checkpoint inhibitors: a new era in autoimmune diabetes
    Akturk, Halis Kaan
    Michels, Aaron W.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2020, 27 (04) : 187 - 193
  • [32] Management of skin adverse events associated with immune checkpoint inhibitors in patients with melanoma: A nursing perspective
    Thebeau, Melissa
    Rubin, Krista
    Hofmann, Matthias
    Grimm, Julia
    Weinstein, Alyona
    Choi, Jennifer N.
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2017, 29 (05) : 294 - 303
  • [33] Pulmonary adverse events following immune checkpoint inhibitors
    Spagnolo, Paolo
    Chaudhuri, Nazia
    Bernardinello, Nicol
    Karampitsakos, Theodoros
    Sampsonas, Fotios
    Tzouvelekis, Argyrios
    CURRENT OPINION IN PULMONARY MEDICINE, 2022, 28 (05) : 391 - 398
  • [34] Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
    Isawa, Tsuyoshi
    Toi, Yukihiro
    Sugawara, Shunichi
    Taguri, Masataka
    Toyoda, Shigeru
    ONCOLOGIST, 2022, 27 (05) : E410 - E419
  • [35] Rheumatological adverse events secondary to immune checkpoint inhibitors
    Garbarino, Maria Cecilia
    Manzano, Natalia
    Messina, Osvaldo
    Zylberman, Marcelo
    REUMATOLOGIA CLINICA, 2023, 19 (04): : 215 - 222
  • [36] Interstitial lung disease induced by fluoxetine: Systematic review of literature and analysis of Vigiaccess, Eudravigilance and a national pharmacovigilance database
    Deidda, Arianna
    Pisanu, Claudia
    Micheletto, Laura
    Bocchetta, Alberto
    Del Zompo, Maria
    Stochino, Maria Erminia
    PHARMACOLOGICAL RESEARCH, 2017, 120 : 294 - 301
  • [37] Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
    Zhou, Chaozheng
    Peng, Shengkun
    Lin, Anqi
    Jiang, Aimin
    Peng, Yuanxi
    Gu, Tianqi
    Liu, Zaoqu
    Cheng, Quan
    Zhang, Jian
    Luo, Peng
    ECLINICALMEDICINE, 2023, 59
  • [38] Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy
    King, G. T.
    Sharma, P.
    Davis, S. L.
    Jimeno, A.
    DRUGS OF TODAY, 2018, 54 (02) : 103 - 122
  • [39] Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
    Ma, Zhuo
    Pei, Jie
    Sun, Ximu
    Liu, Lihong
    Lu, Wenchao
    Guo, Qixiang
    Lyu, Jiayou
    Liu, Yuwei
    Zhang, Yuhui
    Zhao, Zhixia
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [40] Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer
    Zhou, Lin
    Wei, Xin
    FRONTIERS IN IMMUNOLOGY, 2021, 12